Sorin Group, a provider of cardiovascular devices, has achieved a milestone of implanting more than 100,000 Mitroflow Aortic Pericardial Heart Valves worldwide.
The Mitroflow pericardial valve is able to fully replace a malfunctioning or diseased aortic heart valve, offering an effective choice for patients and surgeons.
Sorin’s Mitroflow Aortic Pericardial Heart Valve, since its introduction in Europe in 1982, has demonstrated hemodynamic performance and long-term durability.
Due to its design, the Mitroflow valve is recognized by surgeons worldwide for its versatility and ease of implant, even in the most challenging anatomies, Sorin said.
Sorin Group president Heart Valve Business Unit Davide Bianchi said they are pleased to have reached and exceeded this outstanding milestone.
"This confirms once again that the Mitroflow valve, with its hemodynamics and durability, is an excellent option for aortic valve replacement. These positive results will further encourage us to keep offering this state-of the-art valve to cardiac surgeons and patients worldwide," Bianchi said.